Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
Irene Capelli, Lorenzo Gasperoni, Marco Ruggeri, et al.
Journal of Nephrology (2019) Vol. 33, Iss. 1, pp. 37-48
Closed Access | Times Cited: 63

Showing 26-50 of 63 citing articles:

Mineralocorticoid receptor antagonists in patients with chronic kidney disease
Cosimo Cosimato, Thomas Agoritsas, Thomas A. Mavrakanas
Pharmacology & Therapeutics (2020) Vol. 219, pp. 107701-107701
Open Access | Times Cited: 20
Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
Tadakatsu Nakamura, Atsuhiro Kawaguchi
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 4, pp. 353-365
Open Access | Times Cited: 19
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease
Jaejin An, Fang Niu, John J. Sim
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2021) Vol. 41, Iss. 12, pp. 998-1008
Closed Access | Times Cited: 14
Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care
Silvio Borrelli, Luca De Nicola, Roberto Minutolo, et al.
Nutrients (2021) Vol. 13, Iss. 3, pp. 942-942
Open Access | Times Cited: 13
Effective Perturbations by Small-Molecule Modulators on Voltage-Dependent Hysteresis of Transmembrane Ionic Currents
Sheng‐Nan Wu, Chao‐Liang Wu, Hsin‐Yen Cho, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9453-9453
Open Access | Times Cited: 10
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
Yoshio Sumida, Masashi Yoneda, Hidenori Toyoda, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 4939-4939
Open Access | Times Cited: 13
Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension
Divya Padmanabhan Menon, Guanming Qi, Seung Kyum Kim, et al.
Pulmonary Circulation (2021) Vol. 11, Iss. 3, pp. 1-13
Open Access | Times Cited: 11
Pathophysiology of bilateral hyperaldosteronism
Kazutaka Nanba, William E. Rainey
Current Opinion in Endocrinology Diabetes and Obesity (2022) Vol. 29, Iss. 3, pp. 233-242
Open Access | Times Cited: 8
Zinc oxide nanoparticles and spironolactone-enhanced Nrf2/HO-1 pathway and inhibited Wnt/β-catenin pathway in adenine-induced nephrotoxicity in rats
Amira Awadalla, Eman T. Hamam, Fardous F. El‐Senduny, et al.
Redox Report (2022) Vol. 27, Iss. 1, pp. 249-258
Open Access | Times Cited: 8
Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients
Zuoya Sun, Zhiyuan Chen, Ruihong Liu, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 181-190
Open Access | Times Cited: 4
Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
Qianlan Chen, Guocui Wei, Yanping Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
Irene L. Ennis, Néstor G. Pérez
Frontiers in Cardiovascular Medicine (2021) Vol. 7
Open Access | Times Cited: 9
The Expanding Class of Mineralocorticoid Receptor Modulators: New Ligands for Kidney, Cardiac, Vascular, Systemic and Behavioral Selective Actions
Elisabeta Bădilă
Acta Endocrinologica (Bucharest) (2020) Vol. 16, Iss. 4, pp. 487-496
Open Access | Times Cited: 9
Advances in clinical research in chronic kidney disease
Yutong Zou, Fang Liu, Mark E. Cooper, et al.
Journal of Translational Internal Medicine (2021) Vol. 9, Iss. 3, pp. 146-149
Open Access | Times Cited: 8
Impaired negative feedback and death following acute stress in glucocorticoid receptor knockout Xenopus tropicalis tadpoles
Bidisha Paul, Zachary R. Sterner, Ruchika Bhawal, et al.
General and Comparative Endocrinology (2022) Vol. 326, pp. 114072-114072
Open Access | Times Cited: 6
Post-COVID-19 syndrome increased the requirement for corticosteroids in a dialysis patient with preexisting adrenal insufficiency
Eriko Eguchi
CEN Case Reports (2023) Vol. 12, Iss. 4, pp. 347-351
Open Access | Times Cited: 3
Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers
Tadakatsu Nakamura, H. Shimizu, Atsuhiro Kawaguchi
Clinical Therapeutics (2020) Vol. 42, Iss. 11, pp. 2171-2183.e4
Open Access | Times Cited: 6
Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist
Toru Iijima, Makoto Katoh, Kei Takedomi, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 12, pp. 8127-8143
Closed Access | Times Cited: 4
Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers
Kazutaka Yoshihara, Masato Fukae, Helen Kastrissios, et al.
Drug Metabolism and Pharmacokinetics (2023) Vol. 52, pp. 100516-100516
Open Access | Times Cited: 2
Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR
Ming-shuang Zhou, Shao-ying Zheng, Cheng Chen, et al.
Biochemical Pharmacology (2023) Vol. 220, pp. 115975-115975
Open Access | Times Cited: 2
Diuretics in chronic kidney disease
A. I. Dyadyk, Г. Г. Тарадин, Yu. V. Suliman, et al.
The Russian Archives of Internal Medicine (2020) Vol. 10, Iss. 1, pp. 10-20
Open Access | Times Cited: 5
Primary aldosteronism in elderly, old, and very old patients
Maurizio Cesari, Teresa Maria Seccia, Giuseppe Maiolino, et al.
Journal of Human Hypertension (2020) Vol. 34, Iss. 12, pp. 807-813
Closed Access | Times Cited: 5
Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease
Kristin Watson, Alina Kukin, A Wasik, et al.
Journal of Cardiovascular Pharmacology (2021) Vol. 77, Iss. 6, pp. 685-698
Closed Access | Times Cited: 5
The Road to Better Management in Resistant Hypertension—Diagnostic and Therapeutic Insights
Elisabeta Bădilă, C. Japie, Emma Weiss, et al.
Pharmaceutics (2021) Vol. 13, Iss. 5, pp. 714-714
Open Access | Times Cited: 5
Editorial commentary: Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism
Luís M. Ruilope, Gema Ruiz‐Hurtado, Juan Tamargo
Trends in Cardiovascular Medicine (2021) Vol. 32, Iss. 4, pp. 234-236
Closed Access | Times Cited: 4

Scroll to top